PODD:NGS-Insulet Corporation

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 120.7

Change

+0.45 (+0.37)%

Market Cap

USD 2.13B

Volume

0.40M

Analyst Target

USD 106.56
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insulet Corp is a medical device company that develops, manufactures and sells OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-2.66 (-1.95%)

USD 51.34B
ALGN Align Technology Inc

-4.96 (-1.63%)

USD 22.96B
BRKR Bruker Corporation

-0.95 (-1.13%)

USD 12.93B
SWAV Shockwave Medical Inc

N/A

USD 10.25B
MASI Masimo Corporation

-1.56 (-1.13%)

USD 7.14B
AXNX Axonics Modulation Technologie..

-0.14 (-0.21%)

USD 3.43B
IRTC iRhythm Technologies Inc

+1.64 (+1.49%)

USD 3.36B
QDEL Quidel Corporation

-1.59 (-3.95%)

USD 3.14B
LIVN LivaNova PLC

-1.31 (-2.46%)

USD 3.02B
IART Integra LifeSciences Holdings

+0.12 (+0.38%)

USD 2.64B

ETFs Containing PODD

EDOC:AU BetaShares Digital Health.. 7.22 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 4.35 % 0.00 %

-0.18 (-0.97%)

USD 1.51M
CYBG:LSE VanEck Bionic Engineering.. 3.49 % 0.00 %

-0.17 (-0.97%)

USD 6.05M
FDHT 3.00 % 0.00 %

N/A

N/A
FDHT:XETRA Fidelity Digital Health U.. 2.94 % 0.00 %

-0.02 (-0.97%)

USD 4.79M
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

-0.23 (-0.97%)

USD 0.06B
SLIM 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 52.17% 85% B 88% B+
Dividend Return N/A N/A N/A N/A F
Total Return 52.17% 85% B 88% B+
Trailing 12 Months  
Capital Gain 40.23% 88% B+ 92% A
Dividend Return N/A N/A N/A N/A F
Total Return 40.23% 88% B+ 92% A
Trailing 5 Years  
Capital Gain 219.14% 81% B- 92% A
Dividend Return N/A N/A N/A N/A F
Total Return 219.14% 81% B- 92% A
Average Annual (5 Year Horizon)  
Capital Gain 31.74% 72% C 84% B
Dividend Return 31.74% 72% C 83% B
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 38.54% 59% D- 36% F
Risk Adjusted Return 82.38% 87% B+ 88% B+
Market Capitalization 2.13B 97% N/A 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 536.44 8% 2%
Price/Book Ratio 32.19 4% 4%
Price / Cash Flow Ratio 0.00 69% 79%
Price/Free Cash Flow Ratio 0.00 69% 77%
Management Effectiveness  
Return on Equity 7.22% 86% 61%
Return on Invested Capital N/A N/A N/A
Return on Assets 3.32% 84% 71%
Debt to Equity Ratio 279.10% 11% 6%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.